CAR-T Cell Therapy: The Limitation and Solution
DOI:
https://doi.org/10.54097/2mtyqk43Keywords:
Immunotherapy; cancer; CAR-T; restriction; toxic.Abstract
Driven by breakthroughs in biomedical research, chimeric antigen receptor (CAR) T cell therapy has been a potential new class of the therapy that is now being explored in the field of biology with regard to cancer treatment.These genetically engineered immune cells are designed to selectively target antigens expressed on tumour cells, presenting a novel avenue in immunotherapy. Particularly in liquid tumours such as acute lymphoblastic leukaemia (ALL), the noteworthy therapeutic performance of CAR-T cells highlights their promise in the field of immune treatment research.Nevertheless, despite remarkable achievements, considerable challenges persist. Issues such as an immunosuppressive tumour microenvironment (TME), antigen loss, and restricted CAR-T cell trafficking, especially in the solid tumours, present formidable obstacles. Researchers have proposed strategies that aimed at surmounting these challenges, including the dual-targeted CAR-T cells design and TME modification, which offer promising avenues for advancement. However, unresolved questions linger, emphasizing the ongoing need for innovative solutions.
Downloads
References
A. Majumder, ‘Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures’, Cancers (Basel), vol. 16, no. 1, p. 39, Dec. 2023, doi: 10.3390/cancers16010039.
M. A. Nix and A. P. Wiita, ‘Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments’, Cytotherapy, Mar. 2024, doi: 10.1016/j.jcyt.2024.02.024.
Y. Cui, M. Luo, C. Gu, Y. He, Y. Yao, and P. Li, ‘CAR designs for solid tumours: overcoming hurdles and paving the way for effective immunotherapy’, Biophys Rep, vol. 9, no. 5, pp. 279–297, Oct. 2023, doi: 10.52601/bpr.2023.230020.
M. Martinez and E. K. Moon, ‘CAR T cells for solid tumours: New strategies for finding, infiltrating, and surviving in the tumour microenvironment’, Frontiers in Immunology, vol. 10, no. FEB, 2019, doi: 10.3389/fimmu.2019.00128.
H. K. C. Tang et al., ‘CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours’, Cells, vol. 12, no. 12, p. 1586, Jun. 2023, doi: 10.3390/cells12121586.
T. W. Laetsch et al., ‘Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial’, J Clin Oncol, vol. 41, no. 9, pp. 1664–1669, Mar. 2023, doi: 10.1200/JCO.22.00642.
J. H. Park et al., ‘Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia’, New England Journal of Medicine, vol. 378, no. 5, pp. 449–459, Feb. 2018, doi: 10.1056/NEJMoa1709919.
H. Dai et al., ‘Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia’, J Hematol Oncol, vol. 13, no. 1, p. 30, Apr. 2020, doi: 10.1186/s13045-020-00856-8.
C. C. Kloss et al., ‘Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication’, Mol Ther, vol. 26, no. 7, pp. 1855–1866, Jul. 2018, doi: 10.1016/j.ymthe.2018.05.003.
G. Enblad et al., ‘A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia’, Clinical Cancer Research, vol. 24, no. 24, pp. 6185–6194, Dec. 2018, doi: 10.1158/1078-0432.CCR-18-0426.
R. Chen et al., ‘CAR-T treatment for cancer: prospects and challenges’, Front Oncol, vol. 13, p. 1288383, Dec. 2023, doi: 10.3389/fonc.2023.1288383.
R. Grosser, L. Cherkassky, N. Chintala, and P. S. Adusumilli, ‘Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid tumours’, Cancer Cell, vol. 36, no. 5, pp. 471–482, Nov. 2019, doi: 10.1016/j.ccell.2019.09.006.
E. Lanitis, M. Irving, and G. Coukos, ‘Targeting the tumour vasculature to enhance T cell activity’, Curr Opin Immunol, vol. 33, pp. 55–63, Apr. 2015, doi: 10.1016/j.coi.2015.01.011.
T. Miyamoto et al., ‘B7-H3 Suppresses Antitumour Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression’, Cancer Immunol Res, vol. 10, no. 1, pp. 56–69, Jan. 2022, doi: 10.1158/2326-6066.CIR-21-0407.
M. Hong, S. Talluri, and Y. Y. Chen, ‘Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumours’, Current Opinion in Biotechnology, vol. 84, p. 103020, Dec. 2023, doi: 10.1016/j.copbio.2023.103020.
M. Bellal, J. Malherbe, G. Damaj, and D. Du Cheyron, ‘Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update’, Crit Care, vol. 28, p. 69, Mar. 2024, doi: 10.1186/s13054-024-04851-0.
D. W. Lee et al., ‘T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial’, Lancet, vol. 385, no. 9967, pp. 517–528, Feb. 2015, doi: 10.1016/S0140-6736(14)61403-3.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
